Enzo Biochem Inc. (ENZ)

3.29
0.04 1.20
NYSE : Health Technology
Prev Close 3.33
Open 3.33
Day Low/High 3.24 / 3.39
52 Wk Low/High 2.32 / 6.76
Volume 92.47K
Avg Volume 216.40K
Exchange NYSE
Shares Outstanding 47.24M
Market Cap 171.96M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Enzo Biochem Schedules Teleconference To Discuss Second Quarter 2019 Results Tuesday, March 12, 2019 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss Second Quarter 2019 Results Tuesday, March 12, 2019 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2019 second quarter results Tuesday, March 12, 2019, at 8:30 AM E.

ENZ: Insiders Vs. Shorts

ENZ: Insiders Vs. Shorts

The most recent short interest data was recently released for the 01/15/2019 settlement date, and Enzo Biochem, Inc. is one of the most shorted stocks of the Russell 3000, based on 6.69 "days to cover" versus the median component at 4.81.

Enzo Biochem Reports Fiscal 2019 First Quarter Results

Enzo Biochem Reports Fiscal 2019 First Quarter Results

Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and therapeutics company, today reported operating results for the first fiscal quarter ended October 31, 2018, in addition to providing an update on the company's development of lower cost...

Enzo Biochem Schedules Teleconference To Discuss First Quarter 2019 Results Tuesday, December 11, 2018 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss First Quarter 2019 Results Tuesday, December 11, 2018 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostic and therapeutics company, will hold a conference call to discuss fiscal 2019 first quarter results Tuesday, December 11, 2018, at 8:30 AM E.

Enzo Biochem Reports Publication Of Study On Therapeutic Candidate SK1-I Detailing Promising Results In A Model Of Treatment-Resistant Breast Cancer

Enzo Biochem Reports Publication Of Study On Therapeutic Candidate SK1-I Detailing Promising Results In A Model Of Treatment-Resistant Breast Cancer

Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and therapeutics company, today reported the publication of a study in the Journal of Lipid Research by researchers at a collaborating institution that shows SK1-I, the company's proprietary...

ENZ: Insiders Vs. Shorts

ENZ: Insiders Vs. Shorts

The most recent short interest data was recently released for the 09/28/2018 settlement date, and Enzo Biochem, Inc. is one of the most shorted stocks of the Russell 3000, based on 6.91 "days to cover" versus the median component at 4.65.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: None Downgrades: CCI, ENZ, EQC, RAMP, ROSE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Enzo Biochem Reports Fourth Quarter And Fiscal 2018 Results

Enzo Biochem Reports Fourth Quarter And Fiscal 2018 Results

Enzo Biochem Inc. (NYSE:ENZ), an integrated diagnostic and therapeutics company, today reported results for the fourth quarter and fiscal year ended July 31, 2018, in addition to announcing New York State department of Health's approval of additional...

Enzo Biochem Schedules Teleconference To Discuss Fourth Quarter And Fiscal 2018 Results Tuesday, October 16, 2018 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss Fourth Quarter And Fiscal 2018 Results Tuesday, October 16, 2018 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 fourth quarter and year end results Tuesday, October 16, 2018, at 8:30 AM E.

Enzo Biochem To Acquire New Facility For Manufacturing And Distribution To Advance Its Diagnostic And Therapeutic Growth Strategy

Enzo Biochem To Acquire New Facility For Manufacturing And Distribution To Advance Its Diagnostic And Therapeutic Growth Strategy

Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostic and therapeutics company, announced today that, as part of implementing its growth strategy, it has entered into an agreement to purchase a commercial facility with nearly 36,000 square feet in...

Enzo Biochem Enters Oversold Territory (ENZ)

Enzo Biochem Enters Oversold Territory (ENZ)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Enzo Biochem Reports Validation Of Three High Quality, Low Cost Biomarkers For Detecting Cancers And Their Progression, Especially In Women's Health Area

Enzo Biochem Reports Validation Of Three High Quality, Low Cost Biomarkers For Detecting Cancers And Their Progression, Especially In Women's Health Area

Enzo Biochem Inc. (NYSE:ENZ) today announced the validation of three clinically relevant, cost-efficient biomarker detection tests for charting the progression of various cancers, especially in the field of women's health.

Enzo Biochem Is Now Oversold (ENZ)

Enzo Biochem Is Now Oversold (ENZ)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

RSI Alert: Enzo Biochem (ENZ) Now Oversold

RSI Alert: Enzo Biochem (ENZ) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Enzo Biochem Reports Third Quarter Results

Enzo Biochem Reports Third Quarter Results

Enzo Biochem Inc. (NYSE:ENZ), an integrated diagnostic company, today reported results for the third fiscal quarter and nine months ended April 30, 2018, in addition to noting significant progression of its strategic plan aimed at providing...

Enzo Biochem Schedules Teleconference To Discuss Third Quarter 2018 Results Tuesday, June 12, 2018 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss Third Quarter 2018 Results Tuesday, June 12, 2018 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 third quarter results Tuesday, June 12, 2018, at 8:30 AM E.

Patent Trial And Appeal Board Denies Hologic Challenge To Enzo Biochem Patent Involved In Delaware Infringement Case

Patent Trial And Appeal Board Denies Hologic Challenge To Enzo Biochem Patent Involved In Delaware Infringement Case

Enzo Biochem, Inc. (NYSE:ENZ) and its subsidiary Enzo Life Sciences, Inc.

Relative Strength Alert For Enzo Biochem

Relative Strength Alert For Enzo Biochem

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Enzo Biochem Reports Second Quarter And First Half Results

Enzo Biochem Reports Second Quarter And First Half Results

Enzo Biochem Inc. (NYSE:ENZ) today announced results for the fiscal quarter and six months ended January 31, 2018.

Enzo Biochem Schedules Teleconference To Discuss Second Quarter 2018 Results Tuesday, March 13, 2018 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss Second Quarter 2018 Results Tuesday, March 13, 2018 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 second quarter results Tuesday, March 13, 2018, at 8:30 AM E.

Enzo Biochem Becomes Oversold (ENZ)

Enzo Biochem Becomes Oversold (ENZ)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Enzo Biochem At $5, Earn 9.2% Annualized Using Options

Commit To Buy Enzo Biochem At $5, Earn 9.2% Annualized Using Options

Investors eyeing a purchase of Enzo Biochem, Inc. stock, but tentative about paying the going market price of $6.72/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Enzo Biochem Announces New Validated Cost-Effective Cervical Cancer Biomarker Detection Test

Enzo Biochem Announces New Validated Cost-Effective Cervical Cancer Biomarker Detection Test

Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics company, announced today validation of a cervical cancer biomarker detection test that provides a highly robust and cost-efficient solution for anatomical pathology.

Enzo Biochem is Now Oversold (ENZ)

Enzo Biochem is Now Oversold (ENZ)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Enzo Biochem Reports Improved First Quarter Results

Enzo Biochem Reports Improved First Quarter Results

Enzo Biochem Inc. (NYSE:ENZ) today reported improved operating results for the first fiscal quarter ended October 31, 2017, including year over year double digit revenue growth at Enzo Clinical Labs.

Enzo Biochem Schedules Teleconference To Discuss First Quarter 2018 Results Friday, December 8, 2017 At 8:30 AM E.T.

Enzo Biochem Schedules Teleconference To Discuss First Quarter 2018 Results Friday, December 8, 2017 At 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 first quarter results Friday, December 8, 2017, at 8:30 AM E.

Closing out of a Biotech Position

Enzo Biochem has had some worrying action in price.

Doubling Down on This Biotech Name

Despite the earnings miss, this name has great promise -- and we are doubling our stake on this weakness.

TheStreet Quant Rating: D (Sell)